Global Pseudobulbar Treatment Market, By Drug Type (Prescription Drugs, Over-the-Counter Drugs), Treatment Type (Medication, Occupational Therapy, Others), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Injections, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Pseudobulbar has a huge impact on people all across the world. Pseudobulbar influence (PBA) is a condition characterized by spontaneous, inappropriate snickering or sobbing. It is present in patients with multiple sclerosis (MS), severe cerebrum injury, and Alzheimer's disease. As per the CDC, 5.8 million Americans will be living with Alzheimer's disease in 2020. Around 2 million people in the United States were affected by pseudobulbar influence in 2017. Pseudobulbar influence is primarily linked to neurological disorders, and approximately 30 percent to 35 percent of individuals suffer from sadness. Individuals with neurological difficulties have a higher prevalence of pseudobulbar impact, ranging from 5% to 50%.
Data Bridge Market Research analyses that the pseudobulbar treatment market was valued at USD 2.745 billion in 2021 and is expected to reach USD 5.5.9 billion by 2029, registering a CAGR of 9.30% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Type (Prescription Drugs, Over-the-Counter Drugs), Treatment Type (Medication, Occupational Therapy, Others), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Injections, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Allergan (Ireland), Dr. Reddy's Laboratories Ltd. (India), Lupin (India), Abbott (U.S.), AbbVie Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Pseudobulbar affect (PBA) is a condition marked by uncontrollable and inappropriate laughing or crying. People with specific neurological diseases or injuries, which may impair the brain's regulation of emotion, are more likely to have pseudobulbar affect. Pseudobulbar affect (PBA) treatment aims to minimize the severity and frequency of emotional outbursts. Antidepressants, including tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs), can help lower the severity and frequency of your PBA episodes. Antidepressants used to treat PBA are usually prescribed in lower doses than those used to treat depression. The only medicine approved by the Food and Drug Administration to treat PBA is Nuedexta.
Pseudobulbar Treatment Market Dynamics
Drivers
- Increasing prevalence of pseudobulbar affect
The rising prevalence of pseudobulbar affect is estimated to enhance the pseudobulbar treatment market's growth. Stroke, multiple sclerosis (MS), Parkinson's disease, traumatic brain injury, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease are the various neurological conditions which lead to the emergence of pseudobulbar affect. PBA develops when there is a lack of or loss of voluntary control over emotional responses. A lack of inhibitory or regulatory control over emotional expression is presumably caused by many brain regions along a cerebro-ponto-cerebellar axis. The loss or lack of control over emotional expression may result from disruption of neuronal (nerve) pathways from certain parts of the brain to the cerebellum. Serotonin, norepinephrine, dopamine, and glutamate, among other neurotransmitters, are hypothesized to play a role in PBA.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of pseudobulbar treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, rising initiatives by public and private organizations to spread awareness and the surging geriatric population will expand the pseudobulbar treatment market. Additionally, increasing incidences of brain injuries and sedentary lifestyles of people such as high consumption of alcohol will result in the expansion of pseudobulbar treatment market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the pseudobulbar treatment market growth. The global pseudobulbar therapy market is anticipated to be propelled by new strategies for developing medications with fewer adverse effects. Increased awareness of the disease state and clinical demands and a spike in the proportion of persons suffering from pseudobulbar affect are compelling manufacturers in the pseudobulbar treatment market to invest in the development of new medications that are effective in treating the condition.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of the pseudobulbar treatment market during the forecast period.
Restraints/Challenges
On the other hand, high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the pseudobulbar treatment market. Additionally, side effects involved with treatment options and lack of awareness in emerging markets will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This pseudobulbar treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pseudobulbar treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
According to the severity of symptoms, between 2 and 7 million persons in the United States have PBA, along with the lower number indicating individuals with more severe symptoms.
Pseudobulbar treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Global Pseudobulbar Treatment Market Scope
The pseudobulbar treatment market is segmented on the basis of drug type, treatment type, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Type
- Prescription Drugs
- Over-the-Counter Drugs
Treatment Type
- Medication
- Antidepressants
- Selective Serotonin Reuptake Inhibitors
- Tricyclic Antidepressants
- Nuedexta
- Others
- Occupational Therapy
- Others
Dosage form
- Tablets
- Injections
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Pseudobulbar Treatment Market Regional Analysis/Insights
The pseudobulbar treatment market is analysed and market size insights and trends are provided by country, drug type, treatment type, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the pseudobulbar treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the pseudobulbar treatment market because of the high prevalence of brain disorders in this region. Additionally, rising healthcare expenditure and the presence of major key players will further propel the market's growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to surging prevalence of brain injuries in this region. Also, the development of healthcare infrastructure and rising alcohol consumption will further propel themarket's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Pseudobulbar Treatment Market Share Analysis
The pseudobulbar treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pseudobulbar treatment market.
Some of the major players operating in the pseudobulbar treatment market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Zydus Cadila (India)
- Boehringer Ingelheim International GmbH. (Germany)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Eli Lilly and Company (U.S.)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- Dr. Reddy's Laboratories Ltd. (India)
- Lupin (India)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
SKU-